Jonathan Mow
Chief Executive Officer at PHASEBIO PHARMACEUTICALS, INC.
Jonathan Mow active positions
| Companies | Position | Start | End |
|---|---|---|---|
| PHASEBIO PHARMACEUTICALS, INC. | Director/Board Member | 2014-08-31 | - |
| Chief Executive Officer | 2014-08-31 | - | |
| Corporate Officer/Principal | 2012-12-03 | 2014-08-31 | |
Veralox Therapeutics, Inc.
 Veralox Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Veralox Therapeutics, Inc. develops small molecule therapeutics that treat the underlying pathologies of thrombosis and type 1 diabetes. The company was founded by Jeffrey W. Strovel, David J. Maloney and Matthew B. Boxer and is headquartered in Frederick, MD. | Chief Executive Officer | 2023-06-19 | - |
Career history of Jonathan Mow
Former positions of Jonathan Mow
| Companies | Position | Start | End |
|---|---|---|---|
Amylin Pharmaceuticals, Inc.
 Amylin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amylin Pharmaceuticals, Inc. develops and commercializes medicines for diabetes, obesity, and cardiovascular diseases. The company was founded on September 29, 1987 by Howard E. Greene, Jr. and is headquartered in San Diego, CA. | Corporate Officer/Principal | 2007-02-28 | - |
Corus Pharma, Inc.
 Corus Pharma, Inc. Pharmaceuticals: MajorHealth Technology Corus Pharma, Inc. develops drugs to treat needs in infectious diseases and respiratory areas. The firm's core competencies reside in the identification of drugs, rapid clinical development, and FDA approval of its products. The firm was founded in January 2001 by A. Bruce Montgomery and is headquartered in Seattle, WA. | Founder | 2000-12-31 | 2005-12-31 |
| Corporate Secretary | 2000-12-31 | 2005-12-31 | |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 1994-12-31 | 1996-12-31 |
| Syntex Laboratories, Inc. | Corporate Officer/Principal | - | - |
| Lederle International | Corporate Officer/Principal | - | - |
PathoGenesis Corp
 PathoGenesis Corp BiotechnologyHealth Technology Part of Novartis AG, PathoGenesis Corp is a company that develops and markets innovative treatments for chronic infectious diseases. The company is based in Seattle, WA. The company was founded by Isaac Blech. PathoGenesis was acquired by Chiron Corp. on September 19, 2000 for $639.75 million. | Corporate Officer/Principal | - | - |
Training of Jonathan Mow
| University of California, Berkeley | Undergraduate Degree |
| Tepper School of Business | Masters Business Admin |
Statistics
International
| United States | 11 |
Operational
| Corporate Officer/Principal | 6 |
| Chief Executive Officer | 2 |
| Founder | 1 |
Sectoral
| Health Technology | 7 |
| Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 2 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| PHASEBIO PHARMACEUTICALS, INC. | Health Technology |
| Private companies | 6 |
|---|---|
Corus Pharma, Inc.
Corus Pharma, Inc. Pharmaceuticals: MajorHealth Technology Corus Pharma, Inc. develops drugs to treat needs in infectious diseases and respiratory areas. The firm's core competencies reside in the identification of drugs, rapid clinical development, and FDA approval of its products. The firm was founded in January 2001 by A. Bruce Montgomery and is headquartered in Seattle, WA. | Health Technology |
Amylin Pharmaceuticals, Inc.
Amylin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amylin Pharmaceuticals, Inc. develops and commercializes medicines for diabetes, obesity, and cardiovascular diseases. The company was founded on September 29, 1987 by Howard E. Greene, Jr. and is headquartered in San Diego, CA. | Health Technology |
PathoGenesis Corp
PathoGenesis Corp BiotechnologyHealth Technology Part of Novartis AG, PathoGenesis Corp is a company that develops and markets innovative treatments for chronic infectious diseases. The company is based in Seattle, WA. The company was founded by Isaac Blech. PathoGenesis was acquired by Chiron Corp. on September 19, 2000 for $639.75 million. | Health Technology |
| Lederle International | |
| Syntex Laboratories, Inc. | |
Veralox Therapeutics, Inc.
Veralox Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Veralox Therapeutics, Inc. develops small molecule therapeutics that treat the underlying pathologies of thrombosis and type 1 diabetes. The company was founded by Jeffrey W. Strovel, David J. Maloney and Matthew B. Boxer and is headquartered in Frederick, MD. | Health Technology |
- Stock Market
- Insiders
- Jonathan Mow
- Experience
